Autism

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing...

First of its kind study into digital self-management support for autistic adults reveals significant improvements in anxiety levels and quality of life

Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced...

Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and a 523-gene NGS Panel for Standard Evaluation of Myeloid Cancers

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed...

Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease

–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of...

Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting

A sponsored session will feature Dr. Alex Hastie from Bionano, Dr. Suk See De Ravin from National Institute of Health...

Bionano Announces Commercial Release of New Kits for its Ionic System featuring New Chemistry for Nucleic Acid Extraction from FFPE and Tumor Tissue

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits...

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced...

Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.

Amended U.S. protocol increases loading and maintenance doses to similar range as ex-U.S. expansion cohortsNOVATO, Calif., May 17, 2023 (GLOBE...

error: Content is protected !!